Endocrine Abstracts

A key mechanism of persistent cell survival under testosterone suppression in advanced prostate cancer (PC) is continued Androgen Receptor (AR) activation. This results from AR mutation, overexpression, hyper-activation, and/or expression of constitutively-active AR transcript variants (AR-Vs). AR has an unusually long 3’ untranslated region (3’UTR), which performs vital regulatory roles but is remarkably understudied. Its contribution to continued AR activation unde...

Prostate cancer is currently treated with hormonal therapies, which aim to block the production and/or action of androgens. However, tumours eventually progress to castration-resistant prostate cancer and there is a great need for new therapeutic approaches. We have designed and tested engineered repressors which could be effective in circumstances where current therapies fail. These consist of two modules: an interaction domain, which binds directly to the androgen receptor (...